ANZAMET PASSES RANDOMIZED DOUBLE-BLINDED TRIAL FOR FM PAIN

The 5-HT3 receptor antagonist dolasetron (trade name Anzemet®) is mainly prescribed to reduce activity of the vagus nerve – the nerve that conveys information back & forth between the organs & some skeletal muscles and the brain. Because the vagus nerve is responsible for activating the brain’s vomiting center, dolasetron is used after chemo, surgery, radiation, acute gastroenteritis, etc. to reduce nausea/vomiting

A randomized, double-blind, placebo-controlled trial of dolasetron, a 5-HT3 receptor antagonist, in patients with fibromyalgia – Source: European Journal of Pain, Oct 29, 2010

Objective: The purpose of the study was to evaluate the efficacy and safety of dolasetron for symptomatic relief of pain associated with fibromyalgia (FM).

Methods: This prospective, double-blind, placebo-controlled trial randomly assigned 60 patients with FM to receive placebo (n=31) or dolasetron (n=29) 12.5mg/d via the intravenous route on 4 days at:
• Baseline (M0),
• 1 month (M1),
• 2 months (M2),
• And 3 months (M3),

With follow-up to month 12.

Results: Reduction in pain intensity at M3 was significantly greater in dolasetron-treated patients

I don’t know about you but I really do not think that 3 months on the drug is long enough to satisfy me that it is safe.  Nor does testing it on just 60 patients.  But that remains to be seen.  My main concern is they (meaning all drug companies) do not allow enough time on this or any drug when testing to see the full effects.   I find my body is just getting used to the drug around the 3 month mark let alone what the long term effects are.

Here is the link to the full article:

http://www.prohealth.com/library/showarticle.cfm?libid=15711

Have a Great Day!!

Donna

Advertisements

About Donna

I am a Certified Reiki Practitioner, freelance writer, poet and mentor of Life.
This entry was posted in RESEARCH/STUDIES and tagged , , , , . Bookmark the permalink.